

## Format for ANSWERING REVIEWERS

November 26, 2014



Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 2429-review.doc).

**Title:** Mesalazine-induced cardiopulmonary hypersensitivity. A case report and literature review.

**Authors:** José Ferrusquía, Isabel Pérez-Martínez, Ricardo Gómez de la Torre, María Luisa Fernández-Almira, Ruth de Francisco, Luis Rodrigo, Sabino Riestra

**Name of Journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO:** 13801

The manuscript has been improved according to the suggestions of reviewers:

1 Format has been updated

2 Revision has been made according to the suggestions of the reviewers:

*Reviewer No. 503587:*

- 1) Language corrections were made.
- 2) We agree with the fact that our patient did not develop a severe pericardial effusion since clinical and hemodynamic signs of pericardial tamponade was not seen. The corresponding corrections were made.
- 3) A differential diagnosis in our patient is cardiorespiratory involvement as an extra-intestinal manifestation of UC. We already made the corresponding modification to make that fact clear for readers.
- 4) We made clear 5-ASA don't mean mesalazine by making some corrections.
- 5) Table 1 attempts to summarize the principal characteristics of previously published cases of patients with pulmonary disease related to mesalazine. We believe each column is essential to understand better the most common characteristics of this entity, and that is why we believe it is not desirable to delete any column.
- 6) A table summarizing the principal characteristics of previously published cases of cardiac disease related to mesalazine therapy was made and added as Table 2.

*Reviewer No. 68316:*

- 1) We made clear 5-ASA don't mean mesalazine by making some corrections.
- 2) Language corrections were made.

Reviewer No. 36825:

- 1) We also think that the adverse drug reactions seen in our patient are caused by a drug-induced hypersensitivity and therefore, we already made the corresponding modifications in the article and its title.
- 2) In the case presented, mesalazine suspension and the initiation of corticosteroids were simultaneous. We made the corresponding modification in the case report to denote that fact.
- 3) Our patient was receiving azathioprine at same dose for 13 months prior to admission, throughout his entire hospitalization, and after discharged home. That is why we do not think this drug was related with the patient's symptoms. We made the corresponding modification in the case report to denote that fact, and also wrote something related to the azathioprine in the discussion.
- 4) Our patient had chest pain, dyspnea and tachycardia at diagnosis, when we objective the pericardial effusion in the CT scan. After that, we performed an echocardiogram that confirmed the diagnosis. The echocardiogram description is written in the case report, in the second paragraph, after the description of the second CT scan.

3 References and typesetting were corrected

Thank you again for publishing our manuscript in the *World Journal of Gastroenterology*.

Sincerely yours,

Sabino Riestra, MD  
Servicio de Aparato Digestivo  
Hospital Universitario Central de Asturias  
Avenida Roma s/n, Oviedo  
33011, Asturias, Spain.  
Telephone: + 34-985-108-000, Ext. 38667.  
E-mail: sriestram7@hotmail.com